Compare Levi Strauss & Co. (LEVI) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Tempus AI — how do they compare? Levi Strauss & Co. trades at $18.7 (market cap $7.31B), while Tempus AI trades at $71.05 (market cap $12.58B). The key difference: Tempus AI is the larger of the two by market cap, and Levi Strauss & Co. pays a 3.36% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and Tempus AI for 23 Days on average.
| LEVI | TEM | |
|---|---|---|
Market Cap | $7.31B | $12.58B |
Volume | 13,683,095 | 7,444,569 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $25.53 | $99.28 |
52-Week Low | $17.92 | $41.55 |
Typical Hold Time | 70 Days | 23 Days |
Enterprise Value | $8.86B | $13.21B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $18.70, down 4.15% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 12.53 and consistent earnings beats, including Q3 2026 EPS of $0.48 versus $0.36 expected. Revenue for 2025 was $6.28 billion with a net income margin of 9.2%. Recent news highlights a new CFO appointment and positive analyst expectations for Q3 earnings.
The outlook is positive with a consensus price target of $29.00, implying 55% upside, supported by 78.95% analyst buy ratings. Risks include competitive pressures and recent cybersecurity incidents. The stock's valuation and earnings momentum present a compelling opportunity, though technical weakness warrants monitoring.
Tempus AI (TEM) trades at $70.93, up 0.91% today, with a bullish technical signal and strong analyst support. The stock shows robust revenue growth, with 2026 revenue reaching $1.4B, but remains unprofitable with a net margin of -17.77%. Recent FDA clearance for its ECG-MR AI product and positive ESMO Congress abstracts highlight innovation momentum, though negative cash flow from operations and insider selling pose concerns.
Outlook is cautiously optimistic given 64% buy ratings and a $72.60 consensus target, but profitability challenges and high valuation multiples (P/S 8.61, P/B 28.27) demand scrutiny. Key risks include sustained losses, competitive pressures, and reliance on financing activities for liquidity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
